RU2016151645A3 - - Google Patents

Download PDF

Info

Publication number
RU2016151645A3
RU2016151645A3 RU2016151645A RU2016151645A RU2016151645A3 RU 2016151645 A3 RU2016151645 A3 RU 2016151645A3 RU 2016151645 A RU2016151645 A RU 2016151645A RU 2016151645 A RU2016151645 A RU 2016151645A RU 2016151645 A3 RU2016151645 A3 RU 2016151645A3
Authority
RU
Russia
Application number
RU2016151645A
Other languages
Russian (ru)
Other versions
RU2016151645A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016151645A publication Critical patent/RU2016151645A/ru
Publication of RU2016151645A3 publication Critical patent/RU2016151645A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016151645A 2014-07-01 2015-06-26 Биспецифические гетеродимерные диантитела и их применение RU2016151645A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462019762P 2014-07-01 2014-07-01
US62/019,762 2014-07-01
US201562148920P 2015-04-17 2015-04-17
US62/148,920 2015-04-17
PCT/IB2015/054829 WO2016001810A1 (en) 2014-07-01 2015-06-26 Bispecific heterodimeric diabodies and uses thereof

Publications (2)

Publication Number Publication Date
RU2016151645A RU2016151645A (ru) 2018-08-03
RU2016151645A3 true RU2016151645A3 (enExample) 2019-02-20

Family

ID=53718063

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016151645A RU2016151645A (ru) 2014-07-01 2015-06-26 Биспецифические гетеродимерные диантитела и их применение

Country Status (17)

Country Link
US (2) US9884921B2 (enExample)
EP (1) EP3164417A1 (enExample)
JP (1) JP2017520575A (enExample)
KR (1) KR20170010863A (enExample)
CN (1) CN106661119A (enExample)
AU (2) AU2015283704A1 (enExample)
BR (1) BR112016030740A2 (enExample)
CA (1) CA2895659A1 (enExample)
CO (1) CO2017000016A2 (enExample)
IL (1) IL249889A0 (enExample)
MX (1) MX2016017393A (enExample)
PE (1) PE20170286A1 (enExample)
PH (1) PH12016502491A1 (enExample)
RU (1) RU2016151645A (enExample)
SG (1) SG11201609707WA (enExample)
TW (2) TWI659042B (enExample)
WO (1) WO2016001810A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6753851B2 (ja) 2014-12-05 2020-09-09 メモリアル スローン ケタリング キャンサー センター Ｇタンパク質共役受容体を標的化する抗体および使用の方法
ES2899779T3 (es) 2014-12-05 2022-03-14 Memorial Sloan Kettering Cancer Center Receptores antigénicos quiméricos dirigidos a receptor acoplado a proteína G y usos de los mismos
CA2982682A1 (en) * 2015-04-17 2016-10-20 Amgen Research (Munich) Gmbh Bispecific antibody constructs for cdh3 and cd3
CA2991799A1 (en) 2015-07-15 2017-01-19 Zymeworks Inc. Drug-conjugated bi-specific antigen-binding constructs
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
JP7320943B2 (ja) 2016-04-28 2023-08-04 中外製薬株式会社 抗体含有製剤
JP7050677B2 (ja) * 2016-07-29 2022-04-08 中外製薬株式会社 増強されたｆｖｉｉｉ補因子機能代替活性を有する二重特異性抗体
CN106496331B (zh) * 2016-11-08 2020-03-13 北京智岭生物医药科技有限公司 一种FSH-Fc融合蛋白及其制备方法和用途
CA3053010A1 (en) 2017-02-08 2018-08-16 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN110573528B (zh) * 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
CN110382542B (zh) * 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
JP7029822B2 (ja) * 2017-03-29 2022-03-04 タイペイ・メディカル・ユニバーシティ 抗原特異的ｔ細胞及びその使用
CN108866635B (zh) * 2017-05-09 2021-11-26 安升（上海）医药科技有限公司 多特异性蛋白药物及其文库、以及制备方法和应用
AU2018278809B2 (en) 2017-06-02 2022-03-31 Boston Medical Center Corporation Recombinant ROBO2 proteins, compositions, methods and uses thereof
KR20200019946A (ko) * 2017-06-22 2020-02-25 재단법인 생물기술개발중심 표적 세포-의존적 T 세포 관여 및 활성화 비대칭 헤테로다이머 Fc-ScFv 융합 항체 포맷 및 암 치료에서 그 사용
IL273592B2 (en) 2017-09-29 2025-11-01 Chugai Pharmaceutical Co Ltd Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
KR101973060B1 (ko) * 2017-10-20 2019-04-26 주식회사 녹십자 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
CN109706164A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人和猴cd20与效应细胞抗原的桥接分子及其应用
CN109706163A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用
MX2020003472A (es) 2017-11-01 2020-08-03 Chugai Pharmaceutical Co Ltd Variante e isoforma de anticuerpos con actividad biologica reducida.
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
EP3759129A1 (en) 2018-02-28 2021-01-06 Pfizer Inc Il-15 variants and uses thereof
JP2021523140A (ja) * 2018-05-07 2021-09-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合するタンパク質
SG11202010934SA (en) 2018-05-23 2020-12-30 Pfizer Antibodies specific for gucy2c and uses thereof
ES2984950T3 (es) 2018-05-23 2024-10-31 Pfizer Anticuerpos específicos para CD3 y sus usos
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MA53284A (fr) 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EP3897719A4 (en) * 2018-12-21 2022-11-02 Zhejiang Shimai Pharmaceutical Co., Ltd. Protease cleavable bispecific antibodies and uses thereof
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
CN113416258B (zh) * 2019-10-24 2023-08-29 北京免疫方舟医药科技有限公司 一种多特异性抗体及其制备方法和用途
CN115397853A (zh) 2019-12-17 2022-11-25 辉瑞大药厂 对cd47、pd-l1具特异性的抗体及其用途
IL293351A (en) 2019-12-18 2022-07-01 Pfizer Once daily cancer treatment regimen with a prmt5 inhibitor
CA3174908A1 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
IL297922A (en) 2020-05-06 2023-01-01 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and clec12a
MX2022014180A (es) 2020-05-13 2022-12-02 Pfizer Metodos, terapias y usos para tratar cancer.
KR20230022246A (ko) 2020-07-17 2023-02-14 화이자 인코포레이티드 치료 항체 및 그의 용도
US20230340137A1 (en) 2020-09-14 2023-10-26 Pfizer Inc. Methods, therapies and uses for treating cancer
US20240034786A1 (en) * 2020-12-10 2024-02-01 WuXi Biologics Ireland Limited An antibody against p-cadherin and uses thereof
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
CN114539420B (zh) * 2022-01-20 2024-05-17 荣昌生物制药(烟台)股份有限公司 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
WO2023242769A1 (en) 2022-06-17 2023-12-21 Pfizer Inc. Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
KR20250029954A (ko) 2022-07-05 2025-03-05 화이자 인코포레이티드 피리도[4,3-d]피리미딘 화합물
WO2024074977A1 (en) 2022-10-04 2024-04-11 Pfizer Inc. Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
WO2024084364A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Compounds for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
AU2024253142A1 (en) 2023-04-05 2025-10-16 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024213979A1 (en) 2023-04-10 2024-10-17 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024218686A1 (en) 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
TW202523350A (zh) 2023-08-10 2025-06-16 美商輝瑞股份有限公司 治療癌症之方法，療法及用途
WO2025094035A1 (en) 2023-11-01 2025-05-08 Pfizer Inc. Toll-like receptor agonists and conjugates thereof
WO2025109003A1 (en) 2023-11-21 2025-05-30 3B Pharmaceuticals Gmbh P-cadherin ligands

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382317D1 (de) 1982-03-15 1991-07-25 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1991001752A1 (en) 1989-07-27 1991-02-21 Fred Hutchinson Cancer Research Center Immunosuppressive monoclonal antibodies, hybridomas and methods of transplantation
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5811267A (en) 1990-10-29 1998-09-22 Chiron Corporation Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
EP0672068A4 (en) 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1994013806A1 (en) 1992-12-11 1994-06-23 The Dow Chemical Company Multivalent single chain antibodies
CA2155335C (en) 1993-02-04 2001-06-05 HANS CHRISTIAN THõGERSEN Improved method for the refolding of proteins
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
IT1271461B (it) 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU6873396A (en) 1995-10-16 1997-05-07 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
WO1998002452A2 (en) 1996-07-12 1998-01-22 Mcgill University Compounds and methods for modulating cell adhesion
DE69726003T2 (de) 1996-07-16 2004-08-26 Andreas Plückthun Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
AU6537798A (en) 1997-03-14 1998-10-12 Denise Casentini-Borocz Targeted cytolysis of cancer cells
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ATE461282T1 (de) 1997-10-27 2010-04-15 Bac Ip Bv Multivalente antigenbindende proteine
US6485910B1 (en) 1998-02-09 2002-11-26 Incyte Genomics, Inc. Ras association domain containing protein
HK1041210A1 (zh) 1998-02-19 2002-07-05 埃克斯西特治疗公司 用於调节淋巴细胞活化的组合物及方法
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
US6783961B1 (en) 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
WO1999054440A1 (en) 1998-04-21 1999-10-28 Micromet Gesellschaft Für Biomedizinische Forschung Mbh CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
ES2207278T3 (es) 1998-07-28 2004-05-16 Micromet Ag Heterominicuerpos.
WO2000023087A1 (en) 1998-10-21 2000-04-27 Sunol Molecular Corporation Polyspecific binding molecules and uses thereof
WO2001057188A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
DE19905048A1 (de) 1999-02-08 2000-08-10 Gsf Forschungszentrum Umwelt Verwendung depletorisch oder mitogen wirkender Antikörper in der Immuntherapie
HUP0300369A2 (hu) 2000-04-11 2003-06-28 Genentech, Inc. Többértékű antitestek és alkalmazásuk
CA2405961A1 (en) 2000-04-26 2001-11-01 Elusys Therapeutics, Inc. Bispecific molecules and uses thereof
US20040047854A1 (en) 2001-07-27 2004-03-11 Black Roy A. Human disintegrin protein
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20040053245A1 (en) 2001-02-05 2004-03-18 Tang Y. Tom Novel nucleic acids and polypeptides
WO2002072141A2 (en) 2001-03-09 2002-09-19 William Herman Targeted ligands
WO2002072635A2 (en) 2001-03-13 2002-09-19 University College London Specific binding members
CA2445611A1 (en) 2001-05-31 2002-12-05 Chiron Corporation P-cadherin as a target for anti-cancer therapy
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
ATE477280T1 (de) 2001-06-28 2010-08-15 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8030461B2 (en) 2002-04-15 2011-10-04 Chugai Seiyaku Kabushiki Kaisha Methods for constructing scDb libraries
EP1354600A1 (en) 2002-04-19 2003-10-22 Affimed Therapeutics AG Antibody combination useful for tumor therapy
US20040018493A1 (en) 2002-07-12 2004-01-29 Anastasio Alison E. Haplotypes of the CD3E gene
WO2004009639A1 (ja) 2002-07-18 2004-01-29 Cellfree Sciences Co., Ltd. 単鎖抗体およびその利用
JP2006510735A (ja) 2002-08-19 2006-03-30 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
WO2004110345A2 (en) 2002-10-29 2004-12-23 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
EP1562986A2 (en) 2002-11-14 2005-08-17 Adherex Technologies, Inc. Compounds and methods for modulating functions of classical cadherins
JP2011516026A (ja) 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
WO2004104185A1 (en) 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
RU2005141512A (ru) 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
WO2004106380A2 (en) 2003-05-31 2004-12-09 Micromet Ag Human-anti-human cd3 binding molecules
CA2530972A1 (en) 2003-06-11 2004-12-23 Wyeth Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
PL1639011T3 (pl) 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20070037204A1 (en) 2003-08-08 2007-02-15 Hiroyuki ABURANTAI Gene overexpressed in cancer
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005028507A1 (en) 2003-09-24 2005-03-31 Monash University CRYSTAL STRUCTURE OF CD3ϵϜ/OKT3 COMPLEX
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
ATE435238T1 (de) 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
EP1752471B9 (en) 2005-01-05 2009-04-15 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
EP1856278A2 (en) 2005-02-10 2007-11-21 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
AU2006236439B2 (en) * 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2444421A1 (en) * 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
CA2606227A1 (en) 2005-04-28 2006-11-02 Mcgill University Compounds and methods for modulating cadherin-mediated processes
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
EA014025B1 (ru) 2005-09-12 2010-08-30 Новиммун С.А. Композиции антитела против cd3
EP3178850B1 (en) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
JP5399712B2 (ja) 2005-12-21 2014-01-29 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 可溶性ｃｅａに対する抵抗性を有する医薬組成物
WO2007075672A2 (en) 2005-12-23 2007-07-05 Lankenau Institute For Medical Research Prognostic cancer markers
US20090169572A1 (en) 2006-02-28 2009-07-02 Oncotherapy Science, Inc, Methods for damaging cells using effector functions of anti-cdh3 antibodies
WO2007106507A2 (en) 2006-03-14 2007-09-20 Petrie Howard T Detection of gene expression in mixed sample or tissue
US7951918B2 (en) 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
US8535677B2 (en) 2006-06-06 2013-09-17 Oxford Biotherapeutics, Ltd. Antibody drug conjugate treatment of colorectal cancer
TWI596109B (zh) 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
KR101589759B1 (ko) 2007-04-03 2016-01-29 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 ｃｄ３―입실론 결합 도메인
EP3461842A1 (en) * 2007-04-03 2019-04-03 Amgen Research (Munich) GmbH Cross-species-specific binding domain
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
WO2008149354A2 (en) 2007-06-04 2008-12-11 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of inflammatory diseases and methods of using same
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
KR101561175B1 (ko) 2007-08-20 2015-10-16 온코세라피 사이언스 가부시키가이샤 Ｃｄｈ３ 펩티드 및 이를 포함하는 의약제
CN101842387B (zh) 2007-09-26 2014-05-07 Ucb医药有限公司 双特异性抗体融合物
WO2009055937A1 (en) 2007-11-01 2009-05-07 The Royal Institution For The Advancement Of Learning/Mcgill University Altered n-cadherin processing in tumor cells by furln and proproteln convertase 5a (pc5a)
GB2468232B (en) 2007-11-30 2012-10-24 Glaxo Group Ltd Antigen-bindng constructs
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8435749B2 (en) 2008-06-30 2013-05-07 Oncotherapy Science, Inc. Anti-CDH3 antibodies labeled with radioisotope label and uses thereof
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
BRPI0919840B1 (pt) 2008-10-01 2023-02-28 Amgen Research (Munich) Gmbh Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
CA2738566C (en) 2008-10-01 2024-04-30 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
DK2356153T3 (en) 2008-10-01 2016-07-04 Amgen Res Munich Gmbh Bispecific single CHAIN ​​PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
WO2010040545A1 (en) 2008-10-06 2010-04-15 Novoplant Gmbh Proteolytically stable antibody formats
KR101901458B1 (ko) 2008-10-10 2018-09-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｔｃｒ 복합체 면역치료제
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
AU2010252284A1 (en) 2009-05-27 2011-11-17 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
AR078254A1 (es) 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011031833A2 (en) 2009-09-09 2011-03-17 Theraclone Sciences, Inc. Human anti-cancer antibodies
US20120283415A1 (en) 2009-09-10 2012-11-08 Ucb Pharma S.A. Multivalent Antibodies
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
CA2778334A1 (en) 2009-10-20 2011-04-28 Charlotte Mckee Anti-cd3 antibody dosing in autoimmune disease
JP6007420B2 (ja) 2009-11-04 2016-10-12 ファブラス エルエルシー 親和性成熟に基づく抗体最適化方法
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
WO2011071541A2 (en) 2009-12-11 2011-06-16 The Scripps Research Institute Cadherin modulatory agents
AU2010334974A1 (en) 2009-12-22 2012-07-12 Novartis Ag Tetravalent CD47-antibody constant region fusion protein for use in therapy
US20110165161A1 (en) 2009-12-23 2011-07-07 Shih-Yao Lin Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
EP2519542B1 (en) 2009-12-28 2018-10-10 OncoTherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
CN102014475B (zh) 2010-01-08 2012-01-04 华为技术有限公司 资源映射、码分复用方法及装置
US20120294857A1 (en) 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein
ES2656168T3 (es) 2010-02-10 2018-02-23 Fujifilm Ri Pharma Co., Ltd. Anticuerpo anti cadherina marcado con un metal radioactivo
ES2582001T3 (es) 2010-02-25 2016-09-08 Affimed Gmbh Molécula que se une a antígeno y usos de la misma
WO2011109588A1 (en) 2010-03-03 2011-09-09 Health Research Inc. Novel cd3 epsilon immunogens and antibodies
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
PE20130460A1 (es) 2010-05-03 2013-04-26 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
AU2011286024B2 (en) 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
AR082686A1 (es) 2010-08-13 2012-12-26 Baylor Res Inst Adyuvantes de vacuna que direccionan a los adyuvantes de anticuerpos directamente hacia las celulas presentadoras de antigenos
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
DK2606064T3 (en) 2010-08-16 2015-04-20 Novimmune Sa Methods for generating multispecific and multivalent antibodies
EP3482773A1 (en) 2010-10-08 2019-05-15 City of Hope A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
JP2014015396A (ja) 2010-10-29 2014-01-30 Perseus Proteomics Inc 高い親和性を有する抗ｃｄｈ３抗体
EP3708586A1 (en) 2010-10-29 2020-09-16 Perseus Proteomics Inc. Anti-cdh3 antibody having high internalization capacity
PL2647707T3 (pl) 2010-11-30 2019-02-28 Chugai Seiyaku Kabushiki Kaisha Środek terapeutyczny wywołujący cytotoksyczność
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
AR085633A1 (es) 2011-03-08 2013-10-16 Baylor Res Inst Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
JP2014515598A (ja) 2011-03-10 2014-07-03 エイチシーオー アンティボディ， インク． 二重特異性三鎖抗体様分子
ES2668895T3 (es) 2011-03-16 2018-05-23 Amgen Inc. Variantes de Fc
EP2686348B1 (en) 2011-03-17 2015-12-30 Ramot at Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
CA2830987A1 (en) 2011-03-22 2012-09-27 Baylor Research Institute Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
CA2831294A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
AU2012245260B2 (en) 2011-04-22 2016-09-08 Aptevo Research And Development Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
EA201391753A1 (ru) 2011-05-21 2014-08-29 Макродженикс, Инк. Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
SMT201900239T1 (it) 2011-05-21 2019-05-10 Macrogenics Inc Molecole di legame a cd3 in grado di legare cd3 umano e non umano
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
WO2012162583A1 (en) 2011-05-26 2012-11-29 Ibc Pharmaceuticals, Inc. Design and construction of novel multivalent antibodies
SI2726510T1 (sl) 2011-05-27 2023-06-30 F. Hoffmann - La Roche Ag Dvojno ciljanje
JP2014519338A (ja) 2011-06-16 2014-08-14 ノバルティス アーゲー 治療薬として使用される可溶性タンパク質
US9127061B2 (en) 2011-06-24 2015-09-08 Perseus Proteomics Inc. Anti-human P-cadherin (CDH3) recombinant antibody
US20140242081A1 (en) 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
AU2011373925B2 (en) 2011-07-22 2016-04-28 Affimed Therapeutics Ag Multivalent antigen-binding Fv molecule
WO2013026835A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Fc-free antibodies comprising two fab fragments and methods of use
ES2686327T3 (es) 2011-08-23 2018-10-17 Roche Glycart Ag Moléculas de unión a antígeno biespecíficas
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
BR112014003769B1 (pt) 2011-08-23 2022-05-10 Roche Glycart Ag Molécula de ligação ao antígeno biespecífica ativadora de célula t, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013041865A1 (en) 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
EP2758438A1 (en) 2011-09-23 2014-07-30 Amgen Research (Munich) GmbH Bispecific binding molecules for 5t4 and cd3
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9718893B2 (en) 2011-12-19 2017-08-01 Synimmune Gmbh Bispecific antibody molecule
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20150037334A1 (en) 2012-03-01 2015-02-05 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
HK1206386A1 (en) 2012-04-04 2016-01-08 Perseus Proteomics Inc. Conjugate of anti-cdh3 (p-cadherin) antibody and drug
MX366813B (es) 2012-04-20 2019-07-25 Aptevo Res & Development Llc Polipeptidos de enlace cd3.
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US10647756B2 (en) * 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies

Also Published As

Publication number Publication date
EP3164417A1 (en) 2017-05-10
US20180155452A1 (en) 2018-06-07
SG11201609707WA (en) 2017-01-27
TWI659042B (zh) 2019-05-11
CN106661119A (zh) 2017-05-10
CO2017000016A2 (es) 2017-05-19
AU2018274919A1 (en) 2019-01-03
JP2017520575A (ja) 2017-07-27
PH12016502491A1 (en) 2017-03-22
PE20170286A1 (es) 2017-03-30
MX2016017393A (es) 2017-09-05
TW201936638A (zh) 2019-09-16
AU2015283704A1 (en) 2016-12-15
WO2016001810A1 (en) 2016-01-07
CA2895659A1 (en) 2016-01-01
BR112016030740A2 (pt) 2018-02-20
US9884921B2 (en) 2018-02-06
TW201612194A (en) 2016-04-01
IL249889A0 (en) 2017-03-30
RU2016151645A (ru) 2018-08-03
KR20170010863A (ko) 2017-02-01
US20160002357A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
RU2016151645A3 (enExample)
BR112016003450A2 (enExample)
BR112016017578A2 (enExample)
BR112016018088A2 (enExample)
BR112016017950A2 (enExample)
BR112016012999A2 (enExample)
BR112016017899A2 (enExample)
BR112016017262A2 (enExample)
BR112016011585A2 (enExample)
BR112016018578A2 (enExample)
AP2016009666A0 (enExample)
BR112016017660A2 (enExample)
BR112016015479A2 (enExample)
BR112016017960A2 (enExample)
BR112016015542A2 (enExample)
BR112016016389A2 (enExample)
BR112016017693A2 (enExample)
BR112016015293A2 (enExample)
BR112016018603A2 (enExample)
BR112016011451A2 (enExample)
BR112016018465A2 (enExample)
BR112016017221A2 (enExample)
BR112016015071A2 (enExample)
BR112016017018A2 (enExample)
BR112016017752A2 (enExample)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191115